2022
DOI: 10.1016/j.tranon.2022.101477
|View full text |Cite
|
Sign up to set email alerts
|

Micro-hydrogel injectables that deliver effective CAR-T immunotherapy against 3D solid tumor spheroids

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 12 publications
(11 citation statements)
references
References 42 publications
0
11
0
Order By: Relevance
“…These studies suggest that some cells are more vulnerable when exposed to fluid shear than others 32,33 suggesting that the effects should be verified for each individual cell type tested. However, in our previous work, the flow rate ratio of 4:1 mL −1 (oil versus hydrogel phase) was applied to several cell types (mesenchymal stromal cells, 5,26 human fetal chondroprogenitor cells, 29 human articular chondrocytes, 29 CAR-T cells, 27 coculture of hematopoietic stem cells, and OP9-DL cells (bone marrow stromal cells transduced to express the Notch ligand, Delta-like 1 or 4)) 22 without any negative effects on cell viability. A further reduction in microgel size was achieved by using minimal ID tubing (1.44 mm), which allowed the 33G needle to be used (Figure 4D).…”
Section: Anticipated Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…These studies suggest that some cells are more vulnerable when exposed to fluid shear than others 32,33 suggesting that the effects should be verified for each individual cell type tested. However, in our previous work, the flow rate ratio of 4:1 mL −1 (oil versus hydrogel phase) was applied to several cell types (mesenchymal stromal cells, 5,26 human fetal chondroprogenitor cells, 29 human articular chondrocytes, 29 CAR-T cells, 27 coculture of hematopoietic stem cells, and OP9-DL cells (bone marrow stromal cells transduced to express the Notch ligand, Delta-like 1 or 4)) 22 without any negative effects on cell viability. A further reduction in microgel size was achieved by using minimal ID tubing (1.44 mm), which allowed the 33G needle to be used (Figure 4D).…”
Section: Anticipated Resultsmentioning
confidence: 99%
“…The gelatin provides cell recognition function for cell adhesion and remodeling, while the PEG improves the mechanical properties, enabling a highly biocompatible system that has been proven to support cell viability and function. , However, other polymer formulations, such as the inclusion of functionalized hyaluronic acid are possible, providing the hydrogel precursor can flow through the device and be cross-linked by light postmicrogel fabrication. The procedure can also be adapted for varying cell types. , …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…[ 59 ] Another study combined norbornene‐functionalized gelatin (GelNB) with thiol modified linear PEG to generate micro‐hydrogels with a pipette tip‐based microfluidic device. [ 60 ] A general solid tumor target, the CAR‐72 receptor was fused on to T cells and encapsulated in these micro‐hydrogels to be delivered peritumorally; hydrogel modestly improved expansion and effectively reduced tumor size. [ 60 ] Both studies highlight the benefit of hydrogel delivery and prove that the local administration and sustained release of CAR‐T cells can significantly improve therapeutic effect.…”
Section: Delivery Of T Cells Stimulated Ex Vivomentioning
confidence: 99%
“…In this regard, GelNB hydrogels, either crosslinked by thiol-norbornene photocrosslinking or iEDDA click reaction, have been used for the in situ delivery and transfection of micro RNA (miRNA) in stem cells, [106] for activating or releasing transforming growth factor 𝛽 (TGF𝛽), [55,107] and for delivery of chimeric antigen receptor (CAR-) T cells (CAR-T cells). [108] Carthew et al performed in situ transfection of pro-osteogenic miRNAs in hMSCs encapsulated within a LAP and light-crosslinked GelNB-PEGdiSH hydrogel. [106] Higher mineralization and osteogenic gene expression were observed in hMSCs with in situ transfections of miR-100-5p and miR-143-3p.…”
Section: Delivery Carriersmentioning
confidence: 99%